Read Our Latest Whitepaper
Read Our Latest Whitepaper
Precision medicine tools and in vitro diagnostics segments offer significant growth potential (7 – 17% CAGR to 2034). With the recent evolution from genomics to multiomics and application of AI/ ML techniques to large data sets, early stage ventures have emerged, from predictive diagnostic platforms, to pharmacogenics and liquid biopsy, to capture this growth trend. The time is right for private investors to explore precision diagnostics, with partnership and exit opportunities via life sciences tools, diagnostics and biopharma corporates.
Precision medicine tools and in vitro diagnostics segments offer significant growth potential (7 – 17% CAGR to 2034). With the recent evolution from genomics to multiomics and application of AI/ ML techniques to large data sets, early stage ventures have emerged, from predictive diagnostic platforms, to pharmacogenics and liquid biopsy, to capture this growth trend. The time is right for private investors to explore precision diagnostics, with partnership and exit opportunities via life sciences tools, diagnostics and biopharma corporates.
Our Investment Thesis
Our Investment Thesis
Our Investment Thesis
We focus on pre-seed and seed drug delivery, bio tools and diagnostic companies in the US, UK, Europe, and Israel that have potential to attract venture capital funding and commercial partnerships in the US. We not only provide start-up capital, but also accelerate product-market fit and guide startups through the critical fundraising, partnering and commercialization process in the US market, through our extensive network.
Our approach ensures a clear pathway to scaling, with targeted support in securing follow-on funding and establishing partnerships. We typically exit through partnerships or high-value M&A opportunities—maximizing both investor returns and industry impact.
We focus on pre-seed and seed drug delivery, bio tools and diagnostic companies in the US, UK, Europe, and Israel that have potential to attract venture capital funding and commercial partnerships in the US. We not only provide start-up capital, but also accelerate product-market fit and guide startups through the critical fundraising, partnering and commercialization process in the US market, through our extensive network.
Our approach ensures a clear pathway to scaling, with targeted support in securing follow-on funding and establishing partnerships. We typically exit through partnerships or high-value M&A opportunities—maximizing both investor returns and industry impact.
We focus on pre-seed biopharma platforms, tools and diagnostics companies in the US, UK, Europe, and Israel that have potential to attract venture capital funding and commercial partnerships in the US. We not only provide start-up capital, but also accelerate product-market fit and guide startups through the critical fundraising, partnering and commercialization process in the US market, through our extensive network.
Our approach ensures a clear pathway to scaling, with targeted support in securing follow-on funding and establishing partnerships. We typically exit through partnerships or high-value M&A opportunities–maximizing both investor returns and industry impact.
Portfolio
Our investments span all the way from precision medicine platforms and services to diagnostic tests. Take a look at some of our investments:
Our investments span all the way from precision medicine platforms and services to diagnostic tests.
Why We Invest
Why We Invest
We believe that early stage drug delivery, bio tools and diagnostics are on the cusp of major growth, due to advances in multiomics data and genAI/ agentic AI.
Historically, the sector has been underfunded relative to therapeutics, but recent VC rounds and exist in 2024 and 1H 2025 are showing an uptick in activity, as documented in Pitchbook's Q4 2024 report.
We believe that early stage drug delivery, bio tools and diagnostics are on the cusp of major growth, due to advances in multiomics data and genAI/ agentic AI.
Historically, the sector has been underfunded relative to therapeutics, but recent VC rounds and exist in 2024 and 1H 2025 are showing an uptick in activity, as documented in Pitchbook's Q4 2024 report.
Meet Our Team
Meet Our Team
Get to know the passionate individuals behind our work and discover what drives us.
Get to know the passionate individuals behind our work and discover what drives us.
